{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.7","upperLimit":"71.1","value":"65.4"},{"groupId":"OG001","lowerLimit":"49.1","upperLimit":"61.0","value":"55.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"267"}],"units":"Participants"}],"description":"DCR is the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1. Target lesions - CR: Disappearance of all lesions; any pathological lymph nodes must have reduction in short axis to \\<10 mm. PR: At least a 30% decrease in the sum of diameters of lesions vs the baseline sum. Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non target lesions - CR: Disappearance of all lesions and normalization of tumor marker levels; all lymph nodes must be non-pathological in size. Non-CR/Non-PD: Persistence of lesion(s) and/or maintenance of abnormal tumor marker levels. PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"},{"description":"Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Placebo + Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Randomization to Disease Progression (Up to 29.7 Months)","title":"Percentage of Participants With Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}